Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress

Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T.

CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that a late breaking abstract of interim clinical data from the ReFocus trial for RLY-4008 has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held September 9-13, 2022. The presentation will focus on dose escalation and dose expansion patients with FGFR2 fusion, FGFR inhibitor-naïve cholangiocarcinoma. Relay Therapeutics will host a conference call on September 12, 2022 at 8:00 am E.T. to discuss the results of the presentation.

Late Breaking Oral Presentation Details for RLY-4008:
Title: Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Abstract Number: LBA12
Session Title: Proffered Paper Session 2: GI, Upper Digestive
Date/Time: September 11, 2022 at 3:45 pm C.E.S.T./9:45 am E.T.

The ESMO website indicates that late breaking abstracts will be published on the September 7, 2022 at 7:05 pm E.T.

Conference Call Information

Relay Therapeutics will host a conference call and live webcast on September 12, 2022 at 8:00 am E.T. Registration and dial-in for the conference call may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available following the event.

The presentation from the ESMO Congress will also be available on the Relay Therapeutics website under Publications: https://relaytx.com/publications/.

About RLY-4008

RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties. Preclinically, RLY-4008 demonstrated FGFR2-dependent killing in cancer cell lines and induced regression in in vivo models, while minimal inhibition of other targets was observed, including other members of the FGFR family. In addition, RLY-4008 demonstrated strong activity against known clinical on-target resistance mutations in cellular and in vivo preclinical models. RLY-4008 is currently being evaluated in a clinical trial in patients with advanced or metastatic FGFR2-altered solid tumors with a single arm, potentially registration-enabling cohort for pan-FGFR ("FGFRi") treatment-naïve FGFR2-fusion CCA. To learn more about the clinical trial of RLY-4008, please visit here.